

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

TRAMP-C2

RRID:CVCL_3615

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2731, RRID:CVCL_3615

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3615

Proper Citation: ATCC Cat# CRL-2731, RRID:CVCL_3615

Description: Cell line TRAMP-C2 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Defining Citation: [PMID:9269988](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: TRAMP-C2

Synonyms: TRAMP C2

Cross References: BTO:BTO_0005114, CLO:CLO_0009402, AddexBio:C0019006/5004, ATCC:CRL-2731, Wikidata:Q54972949

ID: CVCL_3615

Vendor: ATCC

Catalog Number: CRL-2731

Record Creation Time: 20220427T221633+0000

Record Last Update: 20260830T000129+0000

Ratings and Alerts

No rating or validation information has been found for TRAMP-C2.

No alerts have been found for TRAMP-C2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gao L, et al. (2026) Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. *Journal for immunotherapy of cancer*, 14(1).

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. *iScience*, 29(6), 116184.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. *Cancer research*, 86(12), 2860.

Bach CA, et al. (2025) A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. *PloS one*, 20(9), e0329014.

Arias-Badia M, et al. (2025) Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4. *JCI insight*, 10(7).

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. *Cell reports. Medicine*, 6(2), 101967.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Luo Y, et al. (2025) Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell fate decisions by neoantigen-specific CD8 + T cells. *bioRxiv : the preprint server for biology*.

Yeon M, et al. (2025) Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity. *Cancer research*, 85(24), 5033.

Van Espen B, et al. (2024) RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential. *Molecular cancer research : MCR*, 22(1), 41.

Wang H, et al. (2024) Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model. *Cancers*,

16(16).

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R β strengthens T cell-mediated anti-tumor therapies. *Cell reports. Medicine*, 5(10), 101747.

Santassusagna S, et al. (2023) Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. *Cancer discovery*, 13(12), 2584.

Linares JF, et al. (2022) The lactate-NAD⁺ axis activates cancer-associated fibroblasts by downregulating p62. *Cell reports*, 39(6), 110792.

Feng Y, et al. (2021) Mechanical Loading-Driven Tumor Suppression Is Mediated by Lrp5-Dependent and Independent Mechanisms. *Cancers*, 13(2).

Bordini J, et al. (2020) Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 26(23), 6387.

Ganaie AA, et al. (2020) Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. *Molecular cancer therapeutics*, 19(12), 2598.

Lu Y, et al. (2020) Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. *Cell*, 180(6), 1081.

Poggio M, et al. (2019) Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. *Cell*, 177(2), 414.

Pai CS, et al. (2019) Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity*, 50(2), 477.